Synpromics 12th in the Deloitte UK Technology Fast 50. Synpromics is delighted to announce that it has been ranked 12th in the Deloitte ‘UK Technology Fast 50’ at the annual awards ceremony in London last night.
Medicines Discovery Catapult and the National Centre for the Replacement, Refinement & Reduction of Animals in Research (NC3Rs) announce strategic collaboration to accelerate the translation of more predictive in vitro research models into new products and services
Medicines Discovery Catapult and the Medical Research Council (MRC) Centre for Drug Safety Science (CDSS) at the University of Liverpool announce strategic collaboration to develop next generation human cell models
Oxford, UK and Melbourne, Australia – 5 November 2018. Enesi Pharma and Sementi, announce they have entered into a collaborative agreement.
The collaboration is focused on the development and evaluation of solid dose versions of Sementis’ lead peanut hypoallergy vaccine and their single vectored chikungunya/Zika vaccine candidates for administration via Enesi Pharma’s ImplaVax® technology
Oxford, UK, 1 November 2018 - In a key point in its growth strategy, Exscientia, the innovative company at the forefront of Artificial Intelligence (AI)-driven drug discovery, is expanding its Oxford presence to the new Schrödinger Building on The Oxford Science Park, one of the UK's leading parks for science and technology companies.